· Screen for purging, stimulant misuse, laxatives and compulsive exercise.
· Behavioral screening should precede initiation of GLP-1 therapy.
· Early psychiatric and nutrition referral improves outcomes.
Priority Medical Psychiatric Nutrition Behavioral Medication
Table 1. Initial Primary Care Management Action Vitals, BMI, labs if indicated Suicide, depression, anxiety screening Dietitian referral Therapy referral Consider evidence-based pharmacotherapy
Initial Treatment Considerations
Medication should never function as a standalone intervention. Rather, pharmacotherapy is most effective when integrated within a broader framework of psychotherapy, nutritional rehabilitation, behavioral monitoring and psychologically informed primary care.
Among pharmacologic options, selective serotonin reuptake inhibitors( SSRIs) remain among the most clinically established treatments for coexisting depressive, anxious and obsessive symptom clusters associated with eating disorders. Fluoxetine has demonstrated particular efficacy in bulimia nervosa and remains FDA-approved for reducing binge-purge frequency. Beyond its antidepressant effects, fluoxetine may help decrease intrusive eating-related thoughts, emotional dysregulation and compulsive behavioral cycling that often perpetuate illness severity.
Other SSRIs, including sertraline and escitalopram, may provide benefit in patients whose presentations are dominated by anxiety, obsessive-compulsive traits, perfectionism or trauma-associated hypervigilance. In many patients, the reduction of shame-driven rumination and anticipatory anxiety surrounding food becomes an essential prerequisite for meaningful nutritional recovery.
For patients with moderate to severe binge-eating disorder, lisdexamfetamine( aka Vyvanse) represents the first FDA-approved pharmacologic treatment specifically indicated for binge reduction. Carefully selected patients may experience meaningful decreases in binge frequency, impulsive consumption and loss-of-control eating episodes. However, clinicians must remain vigilant regarding misuse potential, appetite suppression, insomnia, cardiovascular activation and the possibility of reinforcing restrictive behaviors in psychologically vulnerable individuals.
Additional pharmacologic strategies continue to emerge for patients whose symptom profiles include emotional impulsivity, compulsive overeating, mood instability or addictive behavioral traits. Medications such as topiramate may reduce binge frequency and emotional reactivity, while bupropion may offer benefit in selected patients struggling with depressive fatigue, reward dysregulation and compulsive eating patterns. Naltrexone-containing approaches may further modulate reward-driven eating behaviors when addictive pathways significantly contribute to symptom persistence.
Yet pharmacology alone cannot heal the fractured relationship many patients have with nourishment, self-worth and bodily identity.
Key Takeaways
· Eating disorders commonly present as nonspecific medical complaints.
· The EATH framework provides a structured diagnostic approach.
· GLP-1 therapy requires concurrent behavioral monitoring.
· Primary care clinicians play a pivotal role in early detection and treatment.
Stay tuned for Part II in an upcoming issue, which will include information on nutritional psychiatry, SAINT Intelligence, AI-assisted precision nutrition, the Prasad Principle and the future of integrated eating disorder care.
References
1
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021; 384( 11): 989 – 1002.
2
Treasure J, Duarte TA, Schmidt U. Eating disorders. Lancet. 2020; 395( 10227): 899 – 911.
3
Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012; 18( 6): 618 – 637.
4
Kaye WH, Wierenga CE, Bailer UF, et al. Neurobiology of anorexia nervosa: clinical implications of alterations of serotonin and other neuronal systems. Int J Eat Disord. 2013; 46( 5): 448 – 455.
5
Jacka FN, O’ Neil A, Opie R, et al. A randomised controlled trial of dietary improvement for adults with major depression( the‘ SMILES’ trial). BMC Med. 2017; 15( 1): 23.
6
Kristeller JL, Wolever RQ. Mindfulness-based eating awareness training for treating binge eating disorder. Eat Disord. 2011; 19( 1): 49 – 61.
7
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
Dr. Gupta is a psychiatrist who has practiced in Louisville, Kentucky, for more than three decades. He completed psychiatric residency and fellowship training at the University of Rochester School of Medicine and served as Assistant Professor of Psychiatry and Family Medicine at LSU School of Medicine. Dr. Gupta has held academic appointments including Clinical Professor roles at Sullivan University College of Pharmacy and still fulfills a Clinical Professor role at University of Pikeville School of Osteopathic Medicine. His research interests include mood disorders, schizophrenia, the neurobiology of depression, eating disorder, spiritual medicine and innovative approaches to mental health treatment.
August 2026 21